PTC Therapeutics PTCT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Emflaza | $21.48M-55.1% | $27.06M-46.4% | $35.16M-32.3% | $36.35M-23.1% | $47.79M-16.9% | |
| Other Products | $10.97M+1.4% | $5.99M+82.4% | $9.83M-12.2% | $10.62M-24.1% | $10.82M+27.6% | |
| Sephience | $124.55M— | $91.59M— | $19.56M— | —— | —— | |
| Translarna | $58.98M-31.5% | -$294.92M— | $50.67M-29.9% | $59.47M-15.5% | $86.15M-16.8% | |
| Upstaza And Kebilidi | $9.59M+10.8% | —— | —— | —— | $8.66M+105% | |
| Revenue by Geography | ||||||
| All Other Countries Other Than Russia Brazil And United States | $44.6M-22.6% | $47.69M+49.2% | $40.2M-24.6% | $22.9M-57.1% | $57.62M-2.0% | |
| BR | $41.21M+334% | $5.98M+58.4% | $9.22M-68.4% | $40.95M+34.8% | $9.51M+9.1% | |
| RU | $3.25M-91.6% | $18.7M-62.3% | $25.11M+2,502% | $18.12M+745% | $38.51M-26.8% | |
| US | $136.52M+186% | $111.62M+121% | $56.42M+8.6% | $36.35M-23.1% | $47.79M-16.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does PTC Therapeutics break its business down?
- PTC Therapeutics (PTCT) reports revenue by product across 6 parts — Emflaza, Other Products, Sephience, Translarna1 and Translarna. Each is extracted from the segment footnotes and tracked over time.
- Where does PTC Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in PTC Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
